Publikationen 2023

98. Weis, J., Horneber, M., Otto, S. (2023). Diagnostisches Vorgehen. In: Tumorassoziierte Fatigue. Springer, Berlin, Heidelberg.

97. Otto, S., Horneber, M., Weis, J. (2023). Prävention und Therapie. In: Tumorassoziierte Fatigue. Springer, Berlin, Heidelberg.

96. Horneber, M., Weis, J., Otto, S. (2023). Versorgungssituation: Herausforderungen und Lösungsmöglichkeiten. In: Tumorassoziierte Fatigue. Springer, Berlin, Heidelberg.

95. Aging Associates with Cilium Elongation and Dysfunction in Kidney and Pancreas. Adametz F, Müller A, Stilgenbauer S, Burkhalter MD, Philipp M. Adv Biol (Weinh). 2023 Dec;7(12):e2300194. Epub 2023 Aug 3.

94. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach. Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, Morschhauser F, Mussetti A, Viardot A, Zinzani PL, Sureda A; European Society for Blood and Marrow Transplantation and the European Hematology Association Lymphoma Group. Lancet Haematol. 2023 Dec;10(12):e1006-e1015.

93. Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern Germany. Vahl JM, Nagel G, Abou Kors T, Brand M, von Witzleben A, Sonntag M, Grages A, Theodoraki MN, Greve J, Denkinger M, Dallmeier D, Idel C, Stilgenbauer S, Hoffmann TK, Laban S. Cancer Med. 2023 Dec;12(23):21426-21435. Epub 2023 Dec 1.

92. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, Thiede C, Arnhardt I, Valk PJM, Venditti A, Wei AH, Walter RB, Heuser M. Am J Hematol. 2023 Dec;98(12):1847-1855. Epub 2023 Sep 6.

91. Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies. Gopalakrishnan S, Menon R, Suleiman AA, Kater AP, Stilgenbauer S, Seymour JF, Chyla B, Lu T, Young Kim S, Roberts AW, Woyach JA, Mensing S, Salem AH. Hemasphere. 2023 Nov 17;7(12):e983.

90. Results of VOICE: A global survey of disease-specific knowledge and perspectives of real-world patients with CLL. Tam C, Pinilla-Ibarz J, Castillo CG, Fenili AC, Huntley K, Karakus V, Mattar M, Miroli MA, Moura C, Pavlovsky MA, Piotrowski FN, Šimkovič M, Stilgenbauer S. Blood Adv. 2023 Nov 28;7(22):6819-6828.

89. Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, Döhner K, Döhner H. Leukemia. 2023 Nov;37(11):2336-2337.

88. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Gjærde LK, Peczynski C, Polge E, Kröger N, de Latour RP, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, Potter V, Bunjes D, Erzsebet L, Penack O, Schoemans H, Koenecke C, Basak GW, Perić Z. Bone Marrow Transplant. 2023 Nov;58(11):1279-1281. Epub 2023 Aug 23.

87. AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology. Klever MK, Sträng E, Hetzel S, Jungnitsch J, Dolnik A, Schöpflin R, Schrezenmeier JF, Schick F, Blau O, Westermann J, Rücker FG, Xia Z, Döhner K, Schrezenmeier H, Spielmann M, Meissner A, Melo US, Mundlos S, Bullinger L. Blood Adv. 2023 Nov 14;7(21):6520-6531.

86. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, Döhner K, Döhner H. Leukemia. 2023 Nov;37(11):2187-2196. Epub 2023 Aug 17.

85. AML consolidation therapy: timing matters. Reimann AM, Schalk E, Jost F, Mougiakakos D, Weber D, Döhner H, Récher C, Dumas PY, Ditzhaus M, Fischer T, Sager S. J Cancer Res Clin Oncol. 2023 Nov;149(15):13811-13821. Epub 2023 Aug 3.

84. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS. J Clin Oncol. 2023 Nov 20;41(33):5099-5106. Epub 2023 Jul 21.

83. Prehabilitation in an Integrative Medicine Day Clinic for Patients Undergoing Neoadjuvant Treatment: Single-Center Feasibility Pilot Study. Raff C, Dörr-Harim C, Otto S, Thiele J, Mihaljevic A, Kramer K. JMIR Res Protoc. 2023 Oct 18;12:e46765. doi: 10.2196/46765. PMID: 37851493; PMCID: PMC10620634.

82. Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Schmutz M, Zucknick M, Schlenk RF, Mertens D, Benner A, Weichenhan D, Mücke O, Döhner K, Plass C, Bullinger L, Claus R. Clin Epigenetics. 2023 Oct 26;15(1):171.

81. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Nat Commun. 2023 Oct 23;14(1):6724.

80. Nucleosome repositioning in chronic lymphocytic leukaemia. Piroeva KV, McDonald C, Xanthopoulos C, Fox C, Clarkson CT, Mallm JP, Vainshtein Y, Ruje L, Klett LC, Stilgenbauer S, Mertens D, Kostareli E, Rippe K, Teif VB. Genome Res. 2023 Oct;33(10):1649-1661. Epub 2023 Sep 12.

79. Acquired BTK mutations associated with resistance to non-covalent BTK inhibitors.Qi J, Endres S, Yosifov DY, Tausch E, Dheenadayalan RP, Gao X, Müller A, Schneider C, Mertens D, Gierschik P, Wist M, Jebaraj BMC, Stilgenbauer S. Blood Adv. 2023 Oct 10;7(19):5698-5702.

78. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Haematologica. 2023 Oct 1;108(10):2837-2843.

77. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group. Ann Hematol. 2023 Oct;102(10):2741-2752. Epub 2023 Aug 18.

76. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial. Wei AH, Roboz GJ, Dombret H, Dohner H, Schuh AC, Montesinos P, Selleslag D, Bondarenko SN, Prebet T, Lai Y, Skikne B, Beach CL, Ravandi F. Haematologica. 2023 Oct 1;108(10):2820-2825.

75. An unusual presentation of invasive Fusarium aortitis in a patient who is immunocompromised: A case report. Furaijat G, Bettac L, Kächele M, Grüner B, Skrabal C, Barth TFE, Parlak M, Hagemann JB, Peters L, Walther G, Kersten J.Int J Infect Dis. 2023 Sep;134:102-105. doi: 10.1016/j.ijid.2023.05.069.

74. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Schlenk RF, Weber D, Krzykalla J, Kindler T, Wulf G, Hertenstein B, Salih HR, Südhoff T, Krauter J, Martens U, Wessendorf S, Runde V, Tischler HJ, Bentz M, Koller E, Heuser M, Thol F, Benner A, Ganser A, Döhner K, Döhner H. Sci Rep. 2023 Sep 8;13(1):14809.

73. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics. Wang X, Liu J, Azoitei A, Eiseler T, Meessen S, Jiang W, Zheng X, Makori AW, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, Kleger A, John A, Zengerling F, Wezel F, Bolenz C, Günes C. Cell Mol Life Sci. 2023 Sep 22;80(10):299.

72. Enhancing coping skills through brief interventions during cancer therapy - a quasi-experimental clinical pilot study. Gelse N, Bodschwinna D, Jarczok MN, Wanner M, Volz M, Mayer-Steinacker R, Huober J, Gündel H, Hönig K. Front Psychol. 2023 Sep 7;14:1253423. Epub 2023 Sep 7.

71. All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply. Döhner H, Benner A, Ganser A. Lancet Haematol. 2023 Sep;10(9):e707.

70. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva-Kyuchukova LT, Demeter J, Griffiths EA, Yee KWL, Döhner K, Hao Y, Keer HN, Azab M, Döhner H. Blood Adv. 2023 Sep 12;7(17):5027-5037.

69. Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut. Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert ALL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Blood. 2023 Sep 14;142(11):961-972.

68. Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project. Braulke F, Para S, Alt-Epping B, Tewes M, Bäumer M, Haberland B, Mayer-Steinacker R, Hopprich A, de Wit M, Grabe M, Bender-Säbelkampf S, Weßling C, Aulmann C, Gerlach C, Regincos P, Fischer F, Haarmann S, Huys T, Drygas S, Rambau A, Kiani A, Schnabel A, Buhl C, Seipke S, Hiemer S, Polata S, Meßmann M, Hansmeier A, Anastasiadou L, Letsch A, Wecht D, Hellberg-Naegele M, Krug U, Wedding U, van Oorschot B. J Cancer Res Clin Oncol. 2023 Sep;149(11):8829-8842. Epub 2023 May 5.

67. IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways. Naef P, Radpour R, Jaeger-Ruckstuhl CA, Bodmer N, Baerlocher GM, Doehner H, Doehner K, Riether C, Ochsenbein AF. Sci Signal. 2023 Aug 29;16(800):eadd7705.

66. Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated. d'Almeida S, Markovic S, Hermann P, Bracht H, Peifer J, Ettrich TJ, Imhof A, Zhou S, Weiss M, Viardot A, Rottbauer W, Dahme T. Hum Vaccin Immunother. 2023 Aug 1;19(2):2252239.

65. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. Heitmann JS, Schlenk RF, Dörfel D, Kayser S, Döhner K, Heuser M, Thol F, Kapp-Schwoerer S, Labrenz J, Edelmann D, Märklin M, Vogel W, Bethge W, Walz JS, Große-Hovest L, Steiner M, Jung G, Salih HR. J Hematol Oncol. 2023 Aug 17;16(1):96.

64. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan AA, Furman RR, O'Brien SM, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Palhares de Miranda PA, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Blood. 2023 Aug 24;142(8):687-699.

63. Real-​world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-​2 retrospective chart review study. Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Ubieto AJ, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Siddiqi R, Reitan J, Wade S, Salles G. Br J Haematol. 2023 Aug;202(4):749-759. Epub 2022 Oct 18.

62. Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M. Haematologica. 2023 Aug 1;108(8):2244-2248.

61. Reply to S. Sarosiek et al. Buske C, Dimopoulos MA, Morel P; European Consortium for Waldenström's Macroglobulinemia (ECWM). J Clin Oncol. 2023 Aug 20;41(24):4060-4061. Epub 2023 Jun 22.

60. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study. Manz K, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf TH, Griesshammer M, Nauck M, Völzke H, Heidel FH. Leukemia. 2023 Aug;37(8):1745-1749. Epub 2023 Jun 23.

59. Future Directions in the Frontline Management of Waldenström Macroglobulinemia. Buske C, Palomba ML. Hematol Oncol Clin North Am. 2023 Aug;37(4):719-725. Epub 2023 Jun 1.

58. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Gagelmann N, Eikema DJ, Koster L, Netelenbos T, McDonald A, Stoppa AM, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, Bulabois CE, Delforge M, Bunjes D, Arcese W, Reményi P, Itälä-Remes M, Thurner L, Bolaman AZ, Nabil Y, Lund J, Labussière-Wallet H, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I. Eur J Haematol. Aug;111(2):181-190. Epub 2023 Apr 21.

57. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Bamezai S, Pulikkottil AJ, Yadav T, Vegi NM, Mueller J, Mark J, Mandal T, Feder K, Ihme S, Song C, Rosler R, Wiese S, Hoell JI, Kloetgen A, Karsan A, Kumari A, Wojenski L, Sinha AU, Gonzalez-Menendez I, Quintanilla-Martinez L, Donato E, Trumpp A, Kruse E, Hamperl S, Zou L, Rawat VPS, Buske C. Blood. 2023 Jul 6;142(1):90-105. doi: 10.1182/blood.2022018651.

56. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AF, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling EC, Lindstrom V, Juliusson G, Widmer AA, Goede JS, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP. Blood. 2023 Aug 3;142(5):446-459.

55. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). Maag AH, Swanton H, Kull M, Vegi NM, Feuring M. Cytometry A. 2023 Jul;103(7):551-562. Epub 2023 Jan 31.

54. Optimization of Radiolabeling of a [⁹⁰Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation. Winter G, Hamp-Goldstein C, Fischer G, Kletting P, Glatting G, Solbach C, Herrmann H, Sala E, Feuring M, Döhner H, Beer AJ, Bunjes D, Prasad V. Cancers (Basel). 2023 Jul 18;15(14):3660.

53. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial. Held G, Thurner L, Poeschel V, Ott G, Schmidt C, Christofyllakis K, Viardot A, Borchmann P, Engel-Riedel W, Frickhofen N, Nickelsen M, Shpilberg O, Witzens-Harig M, Griesinger F, Krammer-Steiner B, Neubauer A, de Nully Brown P, Federico M, Glass B, Schmitz N, Wulf G, Truemper L, Bewarder M, Murawski N, Stilgenbauer S, Rosenwald A, Altmann B, Engelhard M, Schmidberger H, Fleckenstein J, Berdel C, Loeffler M, Ziepert M. Hemasphere. 2023 Jul 5;7(7):e917. eCollection 2023 Jul.

52. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, Viardot A, Witzens-Harig M, Dierlamm J, Haenel M, Metzner B, Wulf G, Lengfelder E, Keller UB, Frickhofen N, Nickelsen M, Gaska T, Griesinger F, Mahlberg R, Marks R, Shpilberg O, Lindemann HW, Soekler M, Fischer von Weikersthal L, Kiehl M, Roemer E, Bentz M, Krammer-Steiner B, Trappe R, de Nully Brown P, Federico M, Merli F, Engelhard M, Glass B, Schmitz N, Truemper L, Bewarder M, Hartmann F, Murawski N, Stilgenbauer S, Rosenwald A, Altmann B, Schmidberger H, Fleckenstein J, Loeffler M, Poeschel V, Held G. Hemasphere. 2023 Jul 5;7(7):e904. eCollection 2023 Jul.

51. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, phase 3 trial. Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S,Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati S, Benner A, Schlenk, RF Döhner K, Ganser A; on behalf of the German-Austrian AML Study Group (AMLSG). Lancet Haematol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12.

50. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia. Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk CM, Grotenhuijs F, Müller TA, Onder O, Wagle P, Herling CD, Kleppe M, Wang Z, Coombes KR, Robrecht S, Dalvi PS, Lungu BA, Mayer P, Abruzzo LV, Altmüller J, Gathof BS, Persigehl T, Fischer K, Jebaraj BMC, Rienhoff HY, Ecker RC, Zhao Y, Bruns CJ, Stilgenbauer S, Elenitoba-Johnson KSJ, Hallek M, Schweiger MR, Odenthal M, Vasyutina E, Herling M. Blood. 2023 Jul 6;142(1):44-61.

49. A non-canonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Bamezai S, Pulikkottil AJ, Yadav T, Naidu VM, Mueller J, Mark J, Mandal T, Feder KA, Lehle S, Song C, Rosler R, Wiese S, Hoell JI, Kloetgen A, Karsan A, Kumari A, Wojenski L, Sinha AU, Gonzalez-Menendez I, Quintanilla-Martinez L, Donato E, Trumpp A, Kruse E, Hamperl S, Zou L, Rawat VPS, Buske C. Blood. 2023 Jul 6;142(1):90-105.

48. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia. Gökbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagli A, Starck M, Raffel S, Stoltefuss A, Viardot A, Kreuzer KA, Heidenreich D, Renzelmann A, Wäsch R, Topp MS, Ritter B, Reimer P, Beck J, Westermann J, Wendelin K, Alakel N, Hanoun M, Serve H, Hoelzer D. Haematologica. 2023 Jul 1;108(7):1758-1767.

47. Quantitative Evaluation of COVID-19 Pneumonia CT Using AI Analysis-Feasibility and Differentiation from Other Common Pneumonia Forms. Ebong U, Büttner SM, Schmidt SA, Flack F, Korf P, Peters L, Grüner B, Stenger S, Stamminger T, Kestler H, Beer M, Kloth C.  Diagnostics (Basel). 2023 Jun 20;13(12):2129. doi: 10.3390/diagnostics13122129

46. The German Network for Personalized Medicine to enhance patient care and translational research. Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. Nat Med. 22023 Jun;29(6):1298-1301.

45. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Hemasphere. 2023 Jun 30;7(7):e919. eCollection 2023 Jul.

44. The German Network for Personalized Medicine to enhance patient care and translational research. Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. Nat Med. 2023 Jun;29(6):1298-1301. doi: 10.1038/s41591-023-02354-z.

43. Richter transformation: epigenetics to blame? Yosifov DY, Stilgenbauer S. Blood. 2023 Jun 15;141(24):2915-2917.

42. SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study. Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M. Hemasphere. 2023 Jun 2;7(6):e887.

41. Sarcopenia - Definition, Radiological Diagnosis, Clinical Significance. Vogele D, Otto S, Sollmann N, Haggenmüller B, Wolf D, Beer M, Schmidt SA. Rofo. 2023 May;195(5):393-405. English, German. doi: 10.1055/a-1990-0201. Epub 2023 Jan 11. PMID: 36630983.

40. Monitoring of strength, inflammation and muscle function in allogenic stem-cell transplantation patients - a pilot study for novel biomarker and risk stratification determination. Schulz SVW, Bizjak DA, Moebes E, John L, Wais V, Bunjes D, Sala E, Steinacker JM, Kirsten J. Front Immunol. 2023 May 15;14:1129687.

39. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Hütter-Krönke ML, Neagoie A, Blau IW, Wais V, Vuong L, Gantner A, Ahn J, Penack O, Schnell J, Nogai KA, Eberspächer B, Saadati M, Benner A, Bullinger L, Döhner H, Bunjes D, Sala E. Front Immunol. 2023 May 3;14:1174289.

38. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. Guinn BA, Schuler PJ, Schrezenmeier H, Hofmann S, Weiss J, Bulach C, Götz M, Greiner J. Int J Mol Sci. 2023 May 26;24(11):9285.

37. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET. Wille K, Brouka M, Bernhardt J, Rüfer A, Niculescu-Mizil E, Gotic M, Isfort S, Koschmieder S, Barbui T, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Stegelmann F, Döhner K, Kiladjian JJ, Griesshammer M. Hemasphere. 2023 May 2;7(5):e882. eCollection 2023 May.

36. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. N Engl J Med. 2023 May 11;388(19):1739-1754.

35. The International Consensus Classification of Acute Leukemias of Ambiguous Lineage.  Weinberg OK, Arber DA, Döhner H, Mullighan CG, Orgel E, Porwit A, Stone RM, Borowitz MJ. Blood. 2023 May 4;141(18):2275-2277.

34. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahé B, Troussard X, Hajek R, Viardot A, Tournilhac O, Aurran T, Lepretre S, Zerazhi H, Hivert B, Leblond V, de Guibert S, Brandefors L, Garcia-Sanz R, Gomes da Silva M, Kimby E, Schmelzle B, Kaszynski D, Dreyhaupt J, Muche R, Morel P. J Clin Oncol. 2023 May 10;41(14):2607-2616. Epub 2023 Feb 10.

33. Comorbidities in recipients of low transplant conditioning intensity regimens for acute myeloid leukemia: an ALWP EBMT study. Fein JA, Shouval R, Galimard JE, Labopin M, Socié G, Finke J, Cornelissen JJ, Malladi R, Itälä-Remes M, Chevallier P, Orchard K, Bunjes D, Aljurf M, Rubio MT, Versluis J, Mohty M, Nagler A. Blood Adv. 2023 May 23;7(10):2143-2152.

32. Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform. Maier D, Vehreschild JJ, Uhl B, Meyer S, Berger-Thürmel K, Boerries M, Braren R, Grünwald V, Hadaschik B, Palm S, Singer S, Stuschke M, Juárez D, Delpy P, Lambarki M, Hummel M, Engels C, Andreas S, Gökbuget N, Ihrig K, Burock S, Keune D, Eggert A, Keilholz U, Schulz H, Büttner D, Löck S, Krause M, Esins M, Ressing F, Schuler M, Brandts C, Brucker DP, Husmann G, Oellerich T, Metzger P, Voigt F, Illert AL, Theobald M, Kindler T, Sudhof U, Reckmann A, Schwinghammer F, Nasseh D, Weichert W, von Bergwelt-Baildon M, Bitzer M, Malek N, Öner Ö, Schulze-Osthoff K, Bartels S, Haier J, Ammann R, Schmidt AF, Guenther B, Janning M, Kasper B, Loges S, Stilgenbauer S, Kuhn P, Tausch E, Runow S, Kerscher A, Neumann M, Breu M, Lablans M, Serve H. Eur J Epidemiol. 2023 May;38(5):573-586. Epub 2023 Apr 5.

31. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. Greve G, Andrieux G, Schlosser P, Blagitko-Dorfs N, Rehman UU, Ma T, Pfeifer D, Heil G, Neubauer A, Krauter J, Heuser M, Salih HR, Döhner K, Döhner H, Hackanson B, Boerries M, Lübbert M. Leukemia. 2023 May;37(5):1018-1027. Epub 2023 Apr 6.

30. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial. Gaidzik VI, Paschka P, Schlenk RF, Weber D, Fröhling S, Krämer A, Wäsch R, Westermann J, Mayer K, de Wit M, Fiedler W, Benner A, Heuser M, Thol F, Döhner K, Ganser A, Döhner H. Hemasphere. 2023 Apr 21;7(5):e877.

29. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment. Stevens WBC, Los-de Vries GT, Langois-Jacques C, Clear AJ, Stathi P, Sander B, Rosenwald A, Calaminici M, Hoster E, Hiddemann W, Gaulard P, Salles G, Klapper W, Xerri L, Burton C, Tooze RM, Smith AG, Buske C, Scott DW, Natkunam Y, Advani R, Sehn LH, Raemaekers J, Gribben J, Lockmer S, Kimby E, Kersten MJ, Maucort-Boulch D, Ylstra B, van Dijk E, de Jong D. Hemasphere. 2023 Apr 5;7(4):e863.

28. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson J, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Nat Commun. 2023 Apr 18;14(1):2147.

27. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber RM, Kricheldorf K, Isfort S, Döhner H, Brümmendorf TH, Griesshammer M, Döhner K, Koschmieder S. Leukemia. 2023 Apr;37(4):924-928.

26. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. Wei AH, Döhner H, Sayar H, Ravandi F, Montesinos P, Dombret H, Selleslag D, Porkka K, Jang JH, Skikne B, Beach CL, Prebet T, Zhang G, Risueño A, Ugidos M, See WL, Menezes D, Roboz GJ. Am J Hematol. 2023 Apr;98(4):E84-E87. Epub 2023 Feb 6.

25. 18FDG-PET/CT[1]Scans and Biomarker Levels Predicting Clinical Outcome in Patients with Alveolar Echinococcosis—A Single-Center Cohort Study with 179 Patients.Peters L, Jiang W, Eberhardt N, Hagemann JB, Grüner B, Tappe D. Pathogens. 2023; 12(8):1041. doi: 10.3390/pathogens12081041

24. Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas. Seeling C, Mosca E, Mantel E, Möller P, Barth TFE, Mellert K. Cancers (Basel). 2023 Mar 26;15(7):1977. doi: 10.3390/cancers15071977

23. Report of consensus panel 1 from the 11^th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Semin Hematol. 2023 Mar;60(2):73-79. Epub 2023 Mar 29. PMID: 37099027

22. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Müller T, Vydzhak O, Symeonidis K, Crispatzu G, Mayer P, Blakemore SJ, Goehring G, Newrzela S, Hippler S, Robrecht S, Kreuzer KA, Pallasch C, Krüger M, Lechner A, Fischer K, Stilgenbauer S, Beutner D, Hallek M, Auguin D, Hüttelmaier S, Bloehdorn J, Vasyutina E, Herling M. Blood. 2023 Mar 23;141(12):1425-1441.

21. Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma. Evers M, Schreder M, Stühmer T, Jundt F, Ebert R, Hartmann TN, Altenbuchinger M, Rudelius M, Kuric M, Rindt WD, Steinbrunn T, Langer C, Heredia-Guerrero SC, Einsele H, Bargou RC, Rosenwald A, Leich E. Blood Cancer J. 2023 Mar 23;13(1):43.

20. Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities. Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM. Hemasphere. 2023 Mar 7;7(4):e865. eCollection 2023 Apr. PMID: 36911048 No abstract available.

19. In vivo modeling of CLL transformation to Richter's syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. Ten Hacken E, Sewastianik T, Yin S, Brunsting Hoffmann G, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broseus J, Guieze R, Lucas F, Hernandez-​Sanchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ. Blood Cancer Discov. 2023 Mar 1;4(2):150-169.

18. The proto-​oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Stachelscheid J, Jiang Q, Aszyk CM, Warner K, Bley N, Müller TA, Vydzhak O, Symeonidis K, Crispatzu G, Mayer P, Blakemore SJ, Goehring G, Newrzela S, Hippler S, Robrecht S, Kreuzer KA, Pallasch CP, Krüger M, Lechner A, Fischer K, Stilgenbauer S, Beutner D, Hallek M, Auguin D, Hüttelmaier S, Bloehdorn J, Vasyutina E, Herling M. Blood. 2023 Mar 23;141(12):1425-1441.

17. Editorial: Biology and treatment of high-risk CLL. Tausch E, Malcikova J, Riches JC, Edelmann J. Front Oncol. 2023 Feb 20;12:1109950.

16. A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care. El-Galaly TC, Gaidzik VI, Gaman MA, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben JG, Grønbæk K. Hemasphere. 2023 Feb 21;7(3):e842.

15. Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia. Faehling S, Coelho M, Floerchinger A, Schneider C, Stilgenbauer S, Lichter P, Seiffert M, Roessner PM. Hemasphere. 2023 Feb 22;7(3):e840.

14. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Kutsch N, Holmes EE, Robrecht S, Schüler G, Vehling-​Kaiser U, Decker T, Müller-​Hagen S, Heinisch K, Böttcher S, Ritgen M, Kreuzer KA, Stilgenbauer S, Fink AM, Fischer K, Eichhorst B, Hallek M, Wendtner CM. Leuk Lymphoma. 2023 Feb;64(2):478-482. Epub 2022 Nov 24.  No abstract available.

13. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Future Oncol. 2023 Feb;19(5):345-353. Epub 2023 Feb 23. Review.

12. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Pérez J, Drandi D, Puig N, Gilestro M, García-​Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D'Sa S, Kaščák M, Willenbacher W, Roccaro AM, Poulain S, Morel P, Kyriakou C, Fend F, Vos JMI, Dimopoulos MA, Buske C, Ferrero S, García-​Sanz R. Leukemia. 2023 Feb;37(2):388-395. Epub 2022 Nov 26.

11. Cancer care in German centers of excellence during the first 2 years of the COVID-​19 pandemic. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M. J Cancer Res Clin Oncol. 2023 Feb;149(2):913-919. Epub 2022 Oct 14.

10. Ultra-​Late Osteosarcoma Recurrences: An Analysis of 17 Cooperative Osteosarcoma Study Group Patients with a First Recurrence Detected More Than 10 Years After Primary Tumor Diagnosis. Hecker-​Nolting S, Kager L, Kühne T, Baumhoer D, Blattmann C, Friedel G, von Kalle T, Kevric M, Mayer-​Steinacker R, Schwarz R, Sorg B, Wirth T, Bielack SS. J Adolesc Young Adult Oncol. 2023 Feb;12(1):76-82. Epub 2022 Nov 28.

9. Npm1 Haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. Muranyi A, Ammer T, Kechter A, Rawat VPS, Sinha AU, Gonzalez-Menendez I, Quintanilla-Martinez L, Azoitei A, Günes C, Mupo A, Vassiliou GS, Bamezai S, Buske C. Blood Adv. 2023 Feb 14;7(3):351-364.

8. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Ann Hematol. 2023 Feb;102(2):349-358. Epub 2022 Dec 23.

7. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Am J Hematol. 2023 Feb;98(2):338-347. Epub 2023 Jan 1.

6. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.Broséus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Béné MC, Thieblemont C, Lichter P, Ammerpohl O, Guéant JL; ICGC MMML-Seq Consortium; Guièze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Nat Commun. 2023 Jan 19;14(1):309.

5. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. Blood. 2023 Jan 12;141(2):156-167.

4. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies. Topp M, Dlugosz-Danecka M, Skotnicki AB, Salogub G, Viardot A, Klein AK, Hess G, Michel CS, Grosicki S, Gural A, Schwarz SE, Pietzko K, Gärtner U, Strassz A, Alland L, Mayer J. Trials. 2023 Jan 3;24(1):4.

3. Feasibility, use and benefits of patient-reported outcome measures in palliative care units: a multicentre observational study. Müller E, Mayer-Steinacker R, Gencer D, Keßler J, Alt-Epping B, Schönsteiner S, Jäger H, Couné B, Elster L, Keser M, Rauser J, Marquardt S, Becker G. BMC Palliat Care. 2023 Jan 14;22(1):6.

2. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Nat Med. 2023 Jan;29(1):158-169. Epub 2023 Jan 9.

1. International Consensus Classification for Myeloid Neoplasms At-​A-Glance. Orazi A, Hasserjian RP, Cazzola M, Döhner H, Tefferi A, Arber DA. Am J Hematol. 2023 Jan;98(1):6-10. Epub 2022 Nov 8.